20/20 Biolabs, Inc. splits its revenue into 3 lines in its filings. The largest line in Q2 of fiscal 2026, the quarter ended Jun 30, 2026 was One Test at $695,947, 95% of the total.
USD in millions. The percent under a figure is the change from the same quarter a year earlier.
| Line |
TTM
Jun 30, 2026
|
Q2 FY2026
Jun 30, 2026
|
Q1 FY2026
Mar 31, 2026
|
|---|---|---|---|
| Revenue |
—
|
1
|
0
|
| One Test |
—
|
1
share 95.3%
|
0
share 87.8%
|
| Bio Check |
—
|
0
share 4.7%
|
0
share 6.1%
|
| CLI Ax |
—
|
—
|
0
share 6.1%
|
How these figures are calculated
Quarterly columns are single-quarter amounts. When a 10-Q reports only a year-to-date total, as cash flow statements do, the quarter is that total minus the previous quarter's year-to-date total. The fourth quarter is the annual report's full year minus the first nine months. A column marked YTD is a year-to-date total, shown when the earlier report needed for the single quarter is missing. USD in millions. Each group is a separate split of total revenue, so the groups are not added together. Share of revenue is that line divided by total revenue. The first column adds the latest year-to-date segment amount to the last fiscal year and subtracts the year-ago year-to-date amount. More on our methodology.
Company profile
- Industry
- Services-Testing Laboratories (SIC 8734)
- Listed as
- AIDX (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Rockville, MD
- SEC filer status
- , Emerging growth company
- SEC CIK
- 1139685
- Former names
- 20/20 GeneSystems, Inc. (until Feb 26, 2025); 20/20 GENE SYSTEMS INC (until Apr 28, 2004)
Other Services-Testing Laboratories companies
- UL Solutions Inc. ULS
- Neogenomics Inc NEO
- Hypha Labs, Inc. FUNI
Source: SEC EDGAR filings. This is company-reported data, not investment advice.